QuidelOrtho has been in the headlines after reports it might sell its point-of-care testing unit for about US$1.5b, a move framed as a way to cut debt and refocus on core diagnostics. Investors who held QuidelOrtho from the start of the year are down 54.0%, including dividends. If you had put money to work on 1 January 2026, how much of that drop ties back to what was already on record about its debt, margins and testing mix?
On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.
QuidelOrtho is not the only name tied to this theme. Zero in on 34 healthcare AI stocks and compare how each one is priced.
The Two QuidelOrtho Stories Investors Had To Weigh
The shares cost US$28.56 at the start of the period, and anyone looking at QuidelOrtho had to choose which future felt more reasonable.
The bullish narrative put fair value at US$40.33, based on ideas such as modest 2.6% annual revenue growth and profit margins moving from a loss to 0.6%, supported by global expansion and decentralized testing.
The bearish view set fair value at US$26, assuming 2.5% yearly revenue growth but noting that high debt and cost pressures could keep margins under strain even if markets recovered.
What The Results Put To The Test For QuidelOrtho
QuidelOrtho investors saw revenue of US$630.9m and a loss of US$92.9m in Q2 2026, compared with US$613.9m and a loss of US$255.4m a year earlier. Net margin improved from a loss of 41.6% to a loss of 14.7%, so profitability moved in the right direction but stayed negative. That mix of better margins and ongoing losses cut both ways for the original bullish and cautious stories.
The whole debate hinged on whether modest growth could flip margins into the black. When you look at another diagnostics stock, test that same claim directly against revenue, absolute profit and net margin in each new quarterly report.
What You Would Be Paying For In QuidelOrtho Today
QuidelOrtho now trades at US$13.24 after a 54.0% loss from the start of the year. The selected Narrative’s Fair Value sits above the current price and leans on a repair story built around core Labs and Immunohematology plus already executed cost savings.
A buyer today would need to believe that recurring lab contracts, portfolio upgrades and further cost discipline can offset weak free cash flow, leverage and testing headwinds enough to turn the recent fall into an opening rather than a warning.
"The QuidelOrtho thesis has shifted from a focus on outsized growth and margin expansion to a cleaner, cash flow and balance sheet driven story that emphasizes the stability of core lab franchises and the potential impact of cost savings and portfolio moves on earnings quality."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
Which Company Could Surprise You Next?
Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.
- Company 1 - 41% below our estimate - focuses on expanding higher margin rental mats while managing project timing uncertainties and leadership transitions.
- Company 2 - 30% below our estimate - ties emerging AI tools into established cloud, productivity, coding and security workflows used across enterprises.
- Company 3 - 37% below our estimate - integrates recent acquisitions with cheaper, more diverse deposits to reshape its underlying banking profitability mix.
Those are three of them. See all 29 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com